Leveraging combinatorial chemotherapy to improve outcomes in patients with pancreatic cancer

Cancer Biol Ther. 2010 Jul 1;10(1):108-9. doi: 10.4161/cbt.10.1.12450. Epub 2010 Jul 21.

Authors

Leonidas G Koniaris¹, Xiaoling Jin, Alberto J Montero, Teresa A Zimmers

Affiliation

¹ Department of Surgery, Sylvester Comprehensive Cancer Center, The University of Miami, Miami, FL, USA. lkoniaris@med.miami.edu

PMID: 20581450
DOI: 10.4161/cbt.10.1.12450

No abstract available

Publication types

Comment

MeSH terms

Animals
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab
Cytokines / administration & dosage
Deoxycytidine / administration & dosage
Deoxycytidine / analogs & derivatives
Gemcitabine
Humans
Neoplasm Proteins / administration & dosage
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / metabolism
Pancreatic Neoplasms / pathology
RNA-Binding Proteins / administration & dosage
Survival Rate

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cytokines
Neoplasm Proteins
RNA-Binding Proteins
small inducible cytokine subfamily E, member 1
Deoxycytidine
Bevacizumab
Gemcitabine